Arndt Vogel
@ArndtVogel
Clinician-scientist, focused on liver cancer & precision oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
23-02-2013 08:40:33
1,5K Tweets
5,5K Followers
427 Following
Multicentre phs II trial of cabozantinib in HCC after immune checkpoint inhibitors
Journal of Hepatology
doi.org/10.1016/j.jhep…
🧐Efficacy of Cabozantinib in 2nd line after ICI, but disappointing data in 3rd line
ESMO - Eur. Oncology Milca Malary EASL Education #livertwitter
